preloader

MINDACT - results of clinical trial were presented by Martine Piccart at AACR Annual Meeting 2016 today (New Orleans, Louisiana, USA)

Intro text: 

 

 

NEW ORLEANS — EORTC (European Organisation for Research and Treatment of Cancer), BIG (Breast International Group), and Agendia are pleased to announce that the primary analysis of the EORTC 10041/ BIG 3-04 MINDACT study: a prospective, randomised study evaluating the clinical utility of the 70-gene signature (MammaPrint®) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes” were presented today during the AACR Annual Meeting 2016 (New Orleans, Louisiana, USA – www.aacr.org).

MINDACT is the first prospective randomised controlled clinical trial of a breast cancer recurrence genomic assay with Level 1A clinical evidence. It is also the first prospective translational research study of this magnitude in breast cancer to report the results of its primary objective.

For more information on MINDACT, for additional background information on BIG and/or its clinical trials, or for an interview with a spokesperson from BIG, please contact:

Communications Team :

  • Valerie Van der Veeken : Valerie.VanderVeeken@BIGagainstbc.org
  • Oriana Spagnolo : Oriana.Spagnolo@BIGagainstbc.org   



    Tel.: +32 2 541 3524                 
    www.BIGagainstbreastcancer.org